UBS Starts CarTrade Tech With Buy Rating, Sees Strong Earnings Growth and ₹4,000 Target 
Yaskawa Electric Shares Slide as Weak Profit Overshadows Strong AI Demand 
OpenAI Executive Fidji Simo to Step Down Amid Health Challenges Ahead of IPO 
Kitron Q2 Revenue Beats Estimates as Defense Demand Lifts Growth 
Samsung to Launch First Yongin Chip Plant by 2029 as South Korea Speeds Up Semiconductor Hub 
Deutsche Bank Fined A$2 Million by ASIC Over OTC Derivatives Reporting Errors 
Nvidia Tightens AI Chip Sales in Asia With Stricter Customer Approval Process 
Fast Retailing Raises Full-Year Forecast After Uniqlo Owner Beats Q3 Profit Estimates 
Mastercard Explores Sale of Majority Stake in UK Payments Firm Vocalink: Report 
Muji Owner Ryohin Keikaku Stock Soars After Raising Full-Year Earnings Forecast 
Morgan Stanley Says China’s Reusable Rocket Progress Poses Long-Term Challenge to SpaceX 
Genesis Minerals to Acquire Vault in A$5.6 Billion Deal After Regis Withdraws 
Samsung Chairman Lee Jae-yong Expected to Meet Nvidia CEO Jensen Huang on AI and Chip Partnership 
Stellantis Q2 Vehicle Shipments Rise 10% as North America Drives Growth 
SoftBank Corp Partners With Sierra to Expand AI Customer Support Across Japan 
Morgan Stanley Names Marks & Spencer Top European Retail Pick, Sees Strong Upside 
TSMC Q2 Revenue Surges 36% as AI Chip Demand Powers Growth Ahead of Earnings 
SAN DIEGO, Jan. 06, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the ear, today announced the pricing of an underwritten public offering of 5,000,000 shares of its common stock at a price to the public of $20.00 per share, for total gross proceeds of approximately $100 million before deducting underwriting discounts and commissions and other offering expenses. The offering is expected to close on or about January 12, 2016, subject to customary closing conditions. In addition, Otonomy has granted the underwriters a 30-day option to purchase up to an additional 750,000 shares of its common stock at such offering price, less customary underwriting discounts and commissions. All of the common stock is being sold by Otonomy.
BofA Merrill Lynch, Cowen and Company and Piper Jaffray are acting as joint book-running managers for the offering. Sanford C. Bernstein and SunTrust Robinson Humphrey are acting as co-managers.
A shelf registration statement (File No. 333-206752) was previously filed with the Securities and Exchange Commission (SEC) on September 3, 2015 and became effective on September 14, 2015. A preliminary prospectus supplement relating to and describing the terms of the offering was filed with the SEC on January 5, 2016. The final prospectus supplement relating to the offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. When available, copies of the final prospectus supplement and the accompanying prospectus relating to these securities may also be obtained by contacting one of the following: BofA Merrill Lynch, 222 Broadway, New York, NY 10038, Attn: Prospectus Department, or by email at [email protected]; Cowen and Company, LLC, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department; or Piper Jaffray & Co., 800 Nicollet Mall, Suite 1000, Minneapolis, MN 55402, or by telephone at 800-747-3924, or by email at [email protected].
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.
Contacts: Media Inquiries Canale Communications Heidi Chokeir, Ph.D. Senior Vice President 619.849.5377 [email protected] Investor Inquiries Westwicke Partners Robert H. Uhl Managing Director 858.356.5932 [email protected]
